Abstract:Serum amyloid A (SAA) proteins are acute-phase reactant associated with high-density lipoprotein (HDL) particles and increase in the plasma 1000-fold during inflammation. Recent studies have implicated SAAs in innate immunity and various disorders; however, the precise mechanism eludes us. Previous studies have shown SAAs are elevated following stroke and cerebral ischemia, and our studies demonstrated that SAA-deficient mice reduce inflammation and infarct volumes in a mouse stroke model. Our studies demonstrate that SAA increases the cytokine interleukin-1β (IL-1β), which is mediated by Nod-like receptor protein 3 (NLRP3) inflammasome, cathepsin B, and caspase-1 and may play a role in the pathogenesis of neurological disorders. SAA induced the expression of NLRP3, which mediated IL-1β induction in murine BV-2 cells and both sex primary mouse microglial cells, in a dose- and time-dependent fashion. Inhibition or KO of the NLRP3 in microglia prevented the increase in IL-1β. N-acetyl-l-cysteine and mito-TEMPO blocked the induction of IL-1β by inhibiting ROS with SAA treatment. In addition, inhibition of cathepsin B with different drugs or microglia from CatB-deficient mice attenuated inflammasome activation. Our studies suggest that the impact of SAA on inflammasome stimulation is mediated in part by the receptor for advanced glycation endproducts and Toll-like receptor proteins 2 and 4. SAA induced inflammatory cytokines and an M1 phenotype in the microglial cells while downregulating anti-inflammation M2 phenotype. These studies suggest that brain injury to can elicit a systemic inflammatory response mediated through SAA that contributes to the pathological outcomes.SIGNIFICANCE STATEMENT In the present study, serum amyloid A can induce that activation of the inflammasome in microglial cells and give rise to IL-1β release, which can further inflammation in the brain following neurological diseases. The also presents a novel target for therapeutic approaches in stroke.

Emerging Functions of Serum Amyloid A in Inflammation

Emerging Functions Of Serum Amyloid A In Inflammation

Acute phase reactant serum amyloid A in inflammation and other diseases.

Study on the expression of serum amyloid protein A in vivo in patients with rheumatoid arthritis

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1

Serum amyloid A1: Structure, function and gene polymorphism

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside

Serum Amyloid A Induces M2 Macrophage-Specific Genes Expression and Promotes Efferocytosis of Apoptotic Neutrophils (P5072)

Serum Amyloid A:an Indication of Inflammation in Rheumatoid Arthritis

Ex Vivo and In Vitro Effect of Serum Amyloid A in the Induction of Macrophage M2 Markers and Efferocytosis of Apoptotic Neutrophils

Serum Amyloid A Stimulates PKR Expression and HMGB1 Release Possibly through TLR4/RAGE Receptors

Serum Amyloid A Exhibits Ph Dependent Antibacterial Action and Contributes to Host Defense Against Staphylococcus Aureus Cutaneous Infection.

Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.

Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands

Serum Amyloid a Attenuates Tau Phosphorylation in a Systemic Inflammation Model

Expression of Mouse Acute-Phase (saa1.1) and Constitutive (saa4) Serum Amyloid A Isotypes - Influence on Lipoprotein Profiles

Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in A Mouse Model of Amyloidosis

Jmjd3-mediated Epigenetic Regulation of Inflammatory Cytokine Gene Expression in Serum Amyloid A-stimulated Macrophages.

The Interaction Between Serum Amyloid A and Toll-like Receptor 2 Pathway Regulates Inflammatory Cytokine Secretion in Human Gingival Fibroblasts.

High-Density Lipoproteins and Serum Amyloid A (SAA)

Serum Amyloid A Aggravates Endotoxin-Induced Ocular Inflammation Through the Regulation of Retinal Microglial Activation